Video Clip
Pharma CEO: Daraprim Price Hike is ‘Terribly Unfortunate’
Dr. Francois Nader was CEO of NPS Pharmaceuticals, and recently sold it to Shire Pharmaceuticals for $5.3B. He shares with Privcap his analysis on the Daraprim pricing controversy, in which a new owner of this drug vastly increased the price, causing many to wonder what the effects will be on the pharmaceutical industry.
Register now to watch this video and access all content.
It's FREE!
Privcap Email Updates
Subscribe to receive email notifications whenever new talks are published.